MX2016012932A - Procedimientos novedosos para inducir una respuesta inmune. - Google Patents

Procedimientos novedosos para inducir una respuesta inmune.

Info

Publication number
MX2016012932A
MX2016012932A MX2016012932A MX2016012932A MX2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A
Authority
MX
Mexico
Prior art keywords
inducing
immune response
novel methods
methods
administrations
Prior art date
Application number
MX2016012932A
Other languages
English (en)
Spanish (es)
Inventor
Ripley Ballou William Jr
Ange Demoitie Marie-
Noelle Renelle DONNER Marie-
Ouaked Nadia
Theophile TEMMERMAN Stephane
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2016012932A publication Critical patent/MX2016012932A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2016012932A 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmune. MX2016012932A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
MX2016012932A true MX2016012932A (es) 2016-12-07

Family

ID=50737873

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016012932A MX2016012932A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmune.
MX2016012982A MX2016012982A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2022013912A MX2022013912A (es) 2014-04-02 2016-09-30 Procedimientos novedosos para inducir una respuesta inmunitaria.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016012982A MX2016012982A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2022013912A MX2022013912A (es) 2014-04-02 2016-09-30 Procedimientos novedosos para inducir una respuesta inmunitaria.

Country Status (18)

Country Link
US (3) US10688168B2 (esLanguage)
EP (2) EP3125929B8 (esLanguage)
JP (2) JP6645982B2 (esLanguage)
KR (2) KR20160132115A (esLanguage)
CN (2) CN106456738B (esLanguage)
AR (1) AR099960A1 (esLanguage)
AU (1) AU2015239025B2 (esLanguage)
BE (1) BE1022355B1 (esLanguage)
BR (2) BR112016022463A2 (esLanguage)
CA (2) CA2943711A1 (esLanguage)
EA (1) EA037405B1 (esLanguage)
ES (2) ES2853773T3 (esLanguage)
GB (1) GB201405921D0 (esLanguage)
IL (1) IL247493B (esLanguage)
MX (3) MX2016012932A (esLanguage)
SG (1) SG11201607086QA (esLanguage)
WO (2) WO2015150568A1 (esLanguage)
ZA (1) ZA201605955B (esLanguage)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
RS52187B (sr) 2004-10-14 2012-10-31 Crucell Holland B.V. Vakcine za indukciju i stimulaciju imunskog odgovora za malariju
SI1877426T1 (sl) * 2005-04-29 2012-06-29 Glaxosmithkline Biolog Sa Postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EP2998316B1 (en) * 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Novel method and compositions
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
DK2315834T3 (en) * 2008-07-25 2018-08-20 Glaxosmithkline Biologicals Sa Tuberculosis Rv2386c protein, compositions and uses thereof
JP5824360B2 (ja) * 2008-07-25 2015-11-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物および方法
HUE031044T2 (en) * 2008-07-25 2017-06-28 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
WO2011092253A1 (en) * 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
CN103249431B (zh) * 2010-12-14 2016-11-02 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10004793B2 (en) * 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
JP6645982B2 (ja) 2020-02-14
US10624961B2 (en) 2020-04-21
CN106456738B (zh) 2021-06-29
MX2016012982A (es) 2016-12-07
MX2022013912A (es) 2022-12-13
US10688168B2 (en) 2020-06-23
BR112016022787A2 (pt) 2018-03-27
SG11201607086QA (en) 2016-09-29
ES2961840T3 (es) 2024-03-14
EP3125929C0 (en) 2023-11-01
ES2853773T3 (es) 2021-09-17
EA037405B1 (ru) 2021-03-25
BE1022355A1 (fr) 2016-02-16
AU2015239025B2 (en) 2018-01-25
US20170112914A1 (en) 2017-04-27
BE1022355B1 (fr) 2016-03-26
JP6655549B2 (ja) 2020-02-26
KR102762440B1 (ko) 2025-02-03
US20170136110A1 (en) 2017-05-18
ZA201605955B (en) 2019-04-24
US11951161B2 (en) 2024-04-09
KR20160132115A (ko) 2016-11-16
US20200306353A1 (en) 2020-10-01
IL247493B (en) 2022-08-01
CA2943007C (en) 2024-01-09
CA2943007A1 (en) 2015-10-08
WO2015150568A1 (en) 2015-10-08
EP3125930A1 (en) 2017-02-08
CN106456738A (zh) 2017-02-22
EA201691638A1 (ru) 2017-04-28
GB201405921D0 (en) 2014-05-14
BR112016022463A2 (pt) 2017-10-10
KR20230075525A (ko) 2023-05-31
AU2015239025A1 (en) 2016-09-22
JP2017511324A (ja) 2017-04-20
JP2017511327A (ja) 2017-04-20
EP3125929B8 (en) 2023-12-27
CA2943711A1 (en) 2015-10-08
EP3125929A1 (en) 2017-02-08
CN106456739A (zh) 2017-02-22
AR099960A1 (es) 2016-08-31
EP3125930B1 (en) 2020-12-02
WO2015150567A1 (en) 2015-10-08
EP3125929B1 (en) 2023-11-01
IL247493A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL283058B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL269830B1 (en) Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3134510A4 (en) Recombinant listeria vaccine strains and methods of producing the same
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
EP3112378A4 (en) Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
EP3288538A4 (en) Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
MX2016012932A (es) Procedimientos novedosos para inducir una respuesta inmune.
EP3204414A4 (en) Novel anti-nodal antibodies and methods of using same
MY191539A (en) Streptococcal vaccine
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
EP3107567A4 (en) Methods of modulating an immune response
EP3178491A4 (en) Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
DK3352783T3 (da) Vaccine omfattende immun-isolerede celler som producerer en immunmodulator
PL3402802T3 (pl) Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
EP3151858A4 (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
EP3104887A4 (en) Vaccines with interleukin-17 as an adjuvant
ZA201608104B (en) Co-cultivation of propionibacterium and yeast
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
EP3170068A4 (en) Using timing of character input to verify password
EP3197558A4 (en) Compositions and methods for transient immune response modulation during vaccination